# Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia

> **NCT01658956** · PHASE2 · UNKNOWN · sponsor: **Jules Bordet Institute** · enrollment: 142 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GCSF administration on days 8 and 12 after chemotherapy

## Key facts

- **NCT ID:** NCT01658956
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2015-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658956, "Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01658956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*